Shuoteng's trading volume on March 12 was $463 million, ranking 293rd among U.S. stocks on that day.

K-LinePoet · 2026-04-08T18:16:21+00:00

On March 12, 2026, Zooten (ZTS) achieved a trading volume of $463 million, an increase of 23.79% compared to yesterday, but the stock price fell by 3.61%. Over the past month and this year, the stock price has continued to decline, by 11.93% and 8.23% respectively. Zooten is a leading company in the animal health industry.

K-LinePoet

2026-04-08 18:16:21

Abstract generation in progress

On March 12, 2026, pharmaceutical company Zoetis (ZTS) had trading volume of $463.0 million, ranking 293rd among U.S. stocks on that day. Trading volume increased by 23.79% compared with the previous day, and the trading volume for the day was 3.96M shares.

Zoetis (ZTS) fell 3.61% on March 12, 2026, to $115.46. Over the past 5 trading days, the stock is down 5.54%. For the entire month of March, it is down 11.93%. Year-to-date, it is down 8.23%. Over the past 52 weeks, it is down 28.59%.

*If the company has been listed for less than 52 weeks, then the 52-week percentage change is the percentage change since listing (the same applies to cases where the listing period is less than 1 month or less than 5 trading days)

Zoetis (ZTS)	Trading value/US$	Change in trading value from yesterday	Trading volume
March 12, 2026	$463.0 million	23.79%	3.96M
March 11, 2026	$374.0 million	2.87%	3.13M
March 10, 2026	$363.0 million	-18.25%	2.99M
March 9, 2026	$444.0 million	-14.50%	3.69M
March 6, 2026	$520.0 million	2.15%	4.31M

Zoetis was founded in July 2012 in the U.S. state of Delaware. Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacturing, and commercialization of pharmaceuticals, vaccines, diagnostic products and services, biologics, gene testing, and precision animal health.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes